Compare NSPR & BHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSPR | BHM |
|---|---|---|
| Founded | 2005 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 35.5M |
| IPO Year | 2009 | 2022 |
| Metric | NSPR | BHM |
|---|---|---|
| Price | $0.50 | $8.09 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.33 | N/A |
| AVG Volume (30 Days) | ★ 69.0K | 1.8K |
| Earning Date | 11-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.13% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,310,000.00 | ★ $68,734,000.00 |
| Revenue This Year | $9.14 | $1.31 |
| Revenue Next Year | $105.44 | $11.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.88 |
| 52 Week Low | $0.50 | $7.87 |
| 52 Week High | $2.50 | $13.30 |
| Indicator | NSPR | BHM |
|---|---|---|
| Relative Strength Index (RSI) | 17.89 | 45.98 |
| Support Level | N/A | $8.05 |
| Resistance Level | $1.00 | $8.97 |
| Average True Range (ATR) | 0.07 | 0.30 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 3.12 | 27.50 |
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The company has two reportable segments, consisting of Residential Communities, which derives maximum revenue; and Scattered Single-family homes.